Biotechnology

Smart Meter Introduces World’s First Cellular-Enabled Glucose Meter with Notifications and Multi-Language Capabilities

Retrieved on: 
Sunday, May 5, 2024
Mobile, Wireless, Technology, Medical Devices, Diabetes, Health Technology, Telemedicine, Virtual Medicine, Other Health, Biometrics, Biotechnology, Health, RPM, Pharmacy, Smart, Smart meter, Life, Smartphone, Blood, Patient, LED, Physician, American Telemedicine Association, Multimedia, Patient satisfaction, Howard University, Telehealth, Medical device

iGlucose Plus is available with Spanish language on-screen prompts providing improved access to care to a largely underserved patient population.

Key Points: 
  • iGlucose Plus is available with Spanish language on-screen prompts providing improved access to care to a largely underserved patient population.
  • (Photo: Business Wire)
    The iGlucose Plus is an innovative glucose meter that is easy to use and requires no synching, pairing, smartphone, or Wi-Fi.
  • The new iGlucose Plus is an excellent example of that,” said Casey Pittock, CEO of Smart Meter.
  • The new iGlucose Plus will be on display at the American Telemedicine Association show in Phoenix, Arizona May 5 – 7 at Smart Meter’s booth #1007.

Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS

Retrieved on: 
Sunday, May 5, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Neurology, Mental Health, Health Technology, Medical Devices, Software, FDA, Brain, International Society, Diffusion, GE HealthCare, Hospital, Neuroscience, Doctor of Philosophy, Research, TES, Environment, Mathematics, Microcirculation, Patient, Magnetic resonance, DSM-IV codes, MRI, Diagnosis, Biomarker, Annual general meeting, Medical imaging

SIGNA MAGNUS represents GE HealthCare’s vision of our most advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging.

Key Points: 
  • SIGNA MAGNUS represents GE HealthCare’s vision of our most advanced 3.0T MR imaging device, specifically designed for the highest standards of neurological and oncological research for head-only imaging.
  • Through SIGNA MAGNUS, GE HealthCare will help to empower neuroscientists, neurologists, neuroradiologists and oncologists to transcend barriers, with the goal of enhancing the diagnosis, understanding, and treatment of complex diseases.
  • Researchers can fully utilize SIGNA MAGNUS capabilities to push the boundaries of advanced anatomical, diffusion and functional techniques, amplified by the latest deep-learning algorithms that GE HealthCare has to offer.
  • Additionally, many GE HealthCare 3.0T systems are upgradable to SIGNA MAGNUS, which will help potential customers to save on capital costs.

PDS Biotechnology Announces Details of Virtual KOL Event

Retrieved on: 
Friday, May 3, 2024
University, HNSCC, Section, Pembrolizumab, MD, PDSB, University of North Carolina, KOL, Biotechnology, Patient, Principal, PDS, Harvard Medical School, Immune system, Dana–Farber Cancer Institute, Q&A, Vaccine

PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced additional details of its virtual Key Opinion Leader (KOL) event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.

Key Points: 
  • PRINCETON, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced additional details of its virtual Key Opinion Leader (KOL) event to be held on Wednesday, May 8, 2024 at 1:30 PM ET.
  • To register for the event, click here .
  • The virtual webinar will focus on the positive, updated data from the Company’s VERSATILE-002 Phase 2 clinical trial, current unmet need in HPV-positive head and neck cancer, and next steps for PDS Biotech’s planned triple combination trial including Versamune® HPV and PDS01ADC (IL-12 fused antibody drug conjugate).
  • The VERSATILE-002 trial (NCT04260126) is evaluating Versamune® HPV in combination with the immune checkpoint inhibitor (“ICI”) KEYTRUDA® (pembrolizumab) in patients with unresectable, recurrent, or metastatic HPV16-positive HNSCC.

Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List

Retrieved on: 
Friday, May 3, 2024
UCLA, University, Molecular genetics, University College London, Health, Kyowa Kirin, Pediatrics, Pediatric nursing, Cell, TIME, Patient, Physician, Medicine, HSC, UCL, King's College, Orchard, Therapy, Biotechnology, Pharmaceutical industry

The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .

Key Points: 
  • The full list and related tributes will appear in the May 13, 2024 issue of TIME and is available online at https://time.com/collection/time100-health/ .
  • “I am incredibly humbled, privileged, and immensely proud to be included on this esteemed list of influential and accomplished people shaping the future of health care,” said Dr. Gaspar.
  • “Bobby is a visionary and authentic leader who inspires the very best in his colleagues and peers,” said Frank Thomas, president and chief operating officer of Orchard Therapeutics.
  • Congratulations, Bobby, and thank you for helping carry the mantel for the broader HSC gene therapy field.”

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, May 3, 2024
Sickle cell disease, FDA, Cancer, DSM-IV codes, SCD, News, Food, Blue, Complaint, Class, Bluebird bio, History, Patient, Court, BLA, File, Biotechnology, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial

Retrieved on: 
Saturday, May 4, 2024
Oncology, Health, Surgery, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Stenosis, Administration, Full, Ureteroscopy, Safety, UTUC, American Urological Association, Obstruction, OLYMPUS, Patient, Clutch (eggs), Mitomycins, FRCS, Neoplasm

The study includes a stepwise approach to retrograde administration of JELMYTO and reports that retrograde administration of JELMYTO in the clinic (n=20) produced a 60% complete response rate in patients and ureteral stents were placed in 25% of patients, which is lower than the rate reported in the pivotal OLYMPUS study.

Key Points: 
  • The study includes a stepwise approach to retrograde administration of JELMYTO and reports that retrograde administration of JELMYTO in the clinic (n=20) produced a 60% complete response rate in patients and ureteral stents were placed in 25% of patients, which is lower than the rate reported in the pivotal OLYMPUS study.
  • In the OLYMPUS study 58% (n=41) of patients achieved a complete response, defined as the absence of tumor lesions 3 months after initiation of JELMYTO treatment assessed by urine cytology and ureteroscopy.
  • For additional information about the retrograde administration of JELMYTO, consult the JELMYTO Instructions for Administration accompanying the Full Prescribing Information.
  • Three patients who were unable to tolerate the retrograde approach had antegrade administration of JELMYTO via a nephrostomy tube.

UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024

Retrieved on: 
Saturday, May 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Professor, Disease, DFS, Patient, Cancer, Bladder cancer, ATLAS, NYU, TURBT, Pharmaceutical industry

In the Phase 3 ATLAS study, 282 patients with new or recurrent LG-IR-NMIBC were randomized to primary treatment with UGN-102 ± TURBT or TURBT alone.

Key Points: 
  • In the Phase 3 ATLAS study, 282 patients with new or recurrent LG-IR-NMIBC were randomized to primary treatment with UGN-102 ± TURBT or TURBT alone.
  • In the overall study population, Disease Free Survival (DFS) and DOR favored primary treatment with UGN-102 ± TURBT compared to TURBT alone.
  • Topline data from both the ATLAS trial and the Phase 3 ENVISION trial were initially shared in July of 2023.
  • Twelve-month DOR data from the pivotal Phase 3 ENVISION trial are expected in June 2024.

Mars, Incorporated Enters Exclusive Discussions to Acquire the Entire Stake in French Veterinary Diagnostics Businesses Cerba Vet and ANTAGENE Held by the Cerba HealthCare Group

Retrieved on: 
Friday, May 3, 2024
Veterinary, Biotechnology, Pets, Health, Medical Devices, Wearables, Mobile Technology, Technology, Consumer, Genetics, Laboratory, Pet, Biodiversity, Veterinarian, Hematology, Endocrinology, Serology, Growth, Cat, DNA, Science, Microbiology, Chemistry, Acquisition, Dog, Horse, Veterinary medicine

Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.

Key Points: 
  • Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
  • Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland.
  • Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
  • Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.

UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024

Retrieved on: 
Friday, May 3, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market.

Key Points: 
  • UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2024 first quarter financial results on Monday, May 13, 2024, prior to the open of the stock market.
  • The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
  • A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website.
  • Following the live webcast, a replay will be available on the site for approximately 30 days.

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology

Retrieved on: 
Friday, May 3, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, American Academy, Dermatitis, Phase, LEO, Risk, Delgocitinib, Annual report, Leo Pharma, Tralokinumab, Growth, DKK, Affiliation, CHE, Patient, Acquisition, Psoriasis, AAD, Skin infection, Multimedia, Marketing, Atopic dermatitis, Ichthyosis, Pharmaceutical industry

In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).

Key Points: 
  • In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).
  • Dermatology revenue grew 16% to DKK 2,444 million (Q1 2023: 2,150 million), driven by growth of Adtralza®/Adbry® for atopic dermatitis (AD) and solid growth in the core portfolio.
  • “First quarter marks a solid start to 2024 with a 13% revenue growth and continued progress on our strategic priorities.
  • I am pleased with the strong growth track record for our global dermatology portfolio, primarily driven by performance in North America.